However, and despite all efforts over the past decades, AD still lacks either a cure or a disease modifying therapy to slow down the disease progression, and the currently available pharmacological options are limited to acetylcholinesterase (AchE) inhibitors and the N-methyl-D-aspartate (NMDA) receptor blocker memantine that may only provide modest symptomatic management in AD patients with no capability to alter the disease progression [6]. This evidence concerns the gene ACHE and Alzheimer disease.